Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

Basit Öğe Kaydı
dc.authoridDEMİR, TARIK/0000-0001-6334-4079
dc.authoridDemircan, Nazim/0000-0001-6630-5278
dc.authoridAraz, Murat/0000-0002-4632-9501
dc.authoridKöstek, Osman/0000-0002-1901-5603
dc.authoridSari, Murat/0000-0003-0596-1559
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authorwosidDEMİR, TARIK/AAA-5670-2020
dc.authorwosidDemircan, Nazim/HHY-8715-2022
dc.authorwosidAraz, Murat/C-6388-2015
dc.authorwosidKöstek, Osman/AAA-3604-2019
dc.authorwosidSari, Murat/AAD-4420-2019
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.contributor.authorKostek, Osman
dc.contributor.authorHacioglu, Muhammet Bekir
dc.contributor.authorSakin, Abdullah
dc.contributor.authorDemir, Tarik
dc.contributor.authorSari, Murat
dc.contributor.authorOzkul, Ozlem
dc.contributor.authorAraz, Murat
dc.date.accessioned2024-06-12T11:13:25Z
dc.date.available2024-06-12T11:13:25Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurposeTo assess the efficacy and safety of regorafenib versus rechallenge chemotherapy in previously treated mCRC patients in third-line setting.Materials and methodsThe data of 104 patients diagnosed with mCRC enrolledfrom2010to2017 in six oncology centers were analyzed. Tumor treatment options were obtained from follow-up and treatment files. Rechallenge chemotherapy was identified as the re-use of the regimen which was previously administered to patients in one of the therapy lines and obtained disease control, these were the patients whose disease did not progress within 3months.ResultsA total of 104 patients had received previously two lines of chemotherapy regimens for mCRC. Of these, 73 patients with mCRC who received regorafenib and 31 those who received rechallenge chemotherapy in third-line therapy were analyzed. Overall survival was better with rechallenge than it was with regorafenib (HR 0.29 95% CI 0.16-0.54, p<0.001). Median OS was 12.0months (95% CI 8.1-15.9) in rechallenge versus 6.6months (95% CI 6.0-7.3) in regorafenib group (p<0.001). Progression-free survival in the rechallenge group showed a higher median value of 9.16months (95% CI 7.15-11.18) versus with that recorded in the regorafenib group of 3.41months (95% CI 3.01-3.82), in favor of rechallenge chemotherapy. The most common adverse events of regorafenib was liver function test abnormality and hand-foot syndrome. Although grade 3 or 4 adverse events were similar, non-hematologic toxicities were more common than those of rechallenge.ConclusionsRechallenge is still a valuable option against regorafenib in patients who achieved disease control in one of the first two lines of therapy. Even though mCRC patients treated with regorafenib benefited clinically from this treatment, we revealed that chemotherapy rechallenge compared to regorafenib was more effective in the third-line treatment for mCRC patients.en_US
dc.identifier.doi10.1007/s00280-018-3713-6
dc.identifier.endpage122en_US
dc.identifier.issn0344-5704
dc.identifier.issn1432-0843
dc.identifier.issue1en_US
dc.identifier.pmid30374523en_US
dc.identifier.scopus2-s2.0-85055725125en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage115en_US
dc.identifier.urihttps://doi.org/10.1007/s00280-018-3713-6
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23548
dc.identifier.volume83en_US
dc.identifier.wosWOS:000458407200012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCancer Chemotherapy And Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRechallengeen_US
dc.subjectRegorafeniben_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectOverall Survivalen_US
dc.subjectProgression-Free Survivalen_US
dc.subjectThird-Lineen_US
dc.subjectPhase-Iien_US
dc.subjectBevacizumaben_US
dc.subjectOxaliplatinen_US
dc.subjectPlusen_US
dc.subjectMulticenteren_US
dc.subjectIrinotecanen_US
dc.subjectTherapyen_US
dc.subjectReintroductionen_US
dc.subjectCapecitabineen_US
dc.subjectCombinationen_US
dc.titleRegorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu